Illustrative data only. This is a sample report format, not actual patient data.
Quarterly Employer Report
Acme Manufacturing, Inc.
Headline Metrics
14
Members referred
71%
90-day retention
(baseline: 48.4%)
(baseline: 48.4%)
10
Retained at 90 days
(of 14 referred)
(of 14 referred)
$0
Guarantee credit triggered
Episode Summary
Phase completion (continuity retained)
Navigator thread — continuous across all phases
| Disposition at 90 days | Members | Avg Days | Completion |
|---|---|---|---|
| Induction | 14 | 8 | 100% |
| IOP Active | 13 | 62 | 93% |
| Step-Down | 9 | 45 | 69% |
| Maintenance (active at 90 days) | 7 | ongoing | – |
| Step-down active at 90 days | 1 | ongoing | – |
| Discharge (completed) | 2 | – | – |
| Disengaged / lost to follow-up | 4 | – | – |
Retention vs. Target
Continuum — 90-day retention (continuity won)
National baseline zone
65% target threshold
Outcome Scores (Aggregate)
AUDIT-C0–12 scale
−6.1 pts
Clinically significant improvement
DAST-100–10 scale
−4.6 pts
Substantial to low severity
PHQ-90–27 scale
−7.6 pts
Moderately severe to mild
GAD-70–21 scale
−5.9 pts
Moderate to mild
0 (lower severity)instrument max →
Avg at intake
Avg at 90 days
Lower is better on every instrument
Performance Guarantee
On Track
90-day retention 71% in 14-member cohort, clearing the 65% threshold. Single trigger: retention. Cap: 10% of management fee.
Navigator Accountability
| Metric | Target | Actual | Status |
|---|---|---|---|
| Touchpoint completion rate | 90% | 94% | Met |
| Time to first navigator contact | <48 hrs | 22 hrs avg | Met |
| Missed session follow-up | <24 hrs | 18 hrs avg | Met |
| UDS compliance rate | 80% | 86% | Met |
| Group attendance rate | 75% | 81% | Met |
Equity Snapshot
| Demographic | Members | 90-Day Retention | vs. Cohort Avg |
|---|---|---|---|
| Male | 9 | 71% | −1pt |
| Female | 5 | 74% | +2pt |
| Age 25–34 | 6 | 68% | −4pt |
| Age 35–44 | 5 | 78% | +6pt |
| Age 45+ | 3 | 71% | −1pt |
No subgroup retention is more than 10 percentage points below the cohort average.
Re-disclosure notice (42 CFR Part 2): This report contains aggregate, de-identified data from a substance use disorder treatment program. It is protected by federal confidentiality rules (42 CFR Part 2). It may not be re-disclosed without specific written consent. No individual member can be identified from the data presented.